Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus BLISOVI FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus BLISOVI FE 1 5 30.
ARANELLE vs BLISOVI FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive